Five takeaways from the company’s financial report released Nov. 2:
1. Revenue in the third quarter was $456.4 million, up 12 percent from the same period last year.
2. Net loss was $166.9 million, or $1.35 per share.
3. Screening revenue, which includes Cologuard tests, increased 31 percent to $280.4 million.
4. Precision oncology revenue was $145.4 million, a 59 percent increase compared to the same time last year. COVID-19 testing revenue was $30.6 million, down 70 percent for the same period.
5. Adjusted earnings before interest, taxes, depreciation and amortization was $16.3 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
